Buy SKYRIZI 150 MG RISANKIZUMAB

SKYRIZI 150 MG is a subcutaneous solution containing risankizumab, used for managing moderate to severe plaque psoriasis. This biologic therapy targets specific immune responses to help reduce skin inflammation.

Strength

150 MG

Manufacturer / TM Owner

ABBVIE CORPORATION

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

SKYRIZI 150 MG is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Risankizumab works by targeting specific proteins involved in the immune response, helping to reduce inflammation and skin symptoms associated with psoriasis. This medication is often considered when other treatments have not been effective or are not suitable.

Side Effects

Common effects of SKYRIZI 150 MG may include reactions at the injection site, such as redness, itching, or pain. Some individuals may also experience upper respiratory infections, fatigue, or headache. These effects are generally mild to moderate and may resolve over time. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

SKYRIZI 150 MG should be used with caution in individuals with a history of infections or allergic reactions to biologic therapies. It is important to follow proper handling and storage instructions to maintain the medication's effectiveness. Always inform your healthcare provider about any existing medical conditions or medications you are taking.

Avoid Interactions

SKYRIZI 150 MG may interact with other medications that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the body's response to risankizumab, so it is advisable to consult a healthcare professional for personalized advice.

References

Frequently Asked Questions

SKYRIZI 150 MG is used for the treatment of moderate to severe plaque psoriasis in adults.

SKYRIZI 150 MG is administered via subcutaneous injection, typically self-administered or by a healthcare provider.

Common side effects may include injection site reactions, upper respiratory infections, fatigue, and headache.

It is important to discuss all current medications with a healthcare provider to avoid potential interactions.

SKYRIZI 150 MG should be stored in the refrigerator between 2°C to 8°C and protected from light.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.